Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular.
Focusing on issues ranging from behavioral economics and decision-making based on emerging data to trends such as telemedicine, social media, and the growing role of algorithm-based interventions, Dr. West facilitates data collection and moderates interactive meetings, advisory boards, producing summary reports of current and projected market analysis.
To discuss potential new programs or sponsorship/participation in current ones, please contact Dr. West.
Recent Beacon Media Posts
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still open questions of whether consolidation durvalumab (Imfinzi) in stage III unresectable NSCLC should be discontinued after a year. (6:32)
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation. (7:43)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC. (6:35)